Luminex Will Be Acquired By DiaSorin For About $1.8Bn
Executive Summary
The buyout will broaden DiaSorin’s positioning in the fast-growing molecular diagnostics space and expand Luminex’s foothold outside the US.
Topics
- Subjects
- Financing
- M & A
- Coronavirus COVID-19
- Research & Development
- Commercial
- Device Areas
- Diagnostics
- In Vitro Diagnostics
- Industries
- Medical Device
Latest Headlines
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
MT143780
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.
All fields are required.
MT143780
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.